<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="publisher-id">IENZ</journal-id><journal-id journal-id-type="publisher-id">ienz20</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31431095</article-id><article-id pub-id-type="pmc">6713091</article-id><article-id pub-id-type="doi">10.1080/14756366.2019.1654470</article-id><article-id pub-id-type="publisher-id">1654470</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Exploring new structural features of the 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamide scaffold for the inhibition of human carbonic anhydrases</article-title><alt-title alt-title-type="running-authors">S. Distintoa et&#x000a0;al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1620-6225</contrib-id><name><surname>Distinto</surname><given-names>Simona</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1629-7454</contrib-id><name><surname>Meleddu</surname><given-names>Rita</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref><xref ref-type="corresp" rid="AN0002"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6235-8161</contrib-id><name><surname>Ortuso</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="AF0002"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cottiglia</surname><given-names>Filippo</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Deplano</surname><given-names>Serenella</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5801-9455</contrib-id><name><surname>Sequeira</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Melis</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fois</surname><given-names>Benedetta</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1470-7192</contrib-id><name><surname>Angeli</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="AF0003"><sup>c</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3314-2411</contrib-id><name><surname>Capasso</surname><given-names>Clemente</given-names></name><xref ref-type="aff" rid="AF0004"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Angius</surname><given-names>Rossella</given-names></name><xref ref-type="aff" rid="AF0005"><sup>e</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0437-358X</contrib-id><name><surname>Alcaro</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="AF0002"><sup>b</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4262-0323</contrib-id><name><surname>Supuran</surname><given-names>Claudiu T.</given-names></name><xref ref-type="aff" rid="AF0003"><sup>c</sup></xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2175-2802</contrib-id><name><surname>Maccioni</surname><given-names>Elias</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><aff id="AF0001"><label>a</label><institution>Department of Life and Environmental Sciences, University of Cagliari</institution>, Cagliari, <country>Italy</country>; </aff><aff id="AF0002"><label>b</label><institution>Dipartimento di Scienze della Salute, Universit&#x000e0; Magna Graecia di Catanzaro</institution>, Catanzaro, <country>Italy</country>; </aff><aff id="AF0003"><label>c</label><institution>Dipartimento NEUROFARBA, Sezione di Scienze Farmaceutiche, Universit&#x000e0; degli Studi di Firenze</institution>, Sesto Fiorentino, <country>Italy</country>; </aff><aff id="AF0004"><label>d</label><institution>Istituto di Bioscienze e Biorisorse, CNR</institution>, Napoli, <country>Italy</country>; </aff><aff id="AF0005"><label>e</label><institution>Laboratorio NMR e Tecnologie Bioanalitiche</institution>, Pula, <country>Italy</country></aff></contrib-group><author-notes><corresp id="AN0001">CONTACT Claudiu T. Supuran <email>claudiu.supuran@unifi.it</email><institution>Dipartimento NEUROFARBA, Sezione di Scienze Farmaceutiche, Universit&#x000e0; degli Studi di Firenze</institution>, Sesto Fiorentino, Florence, <country>Italy</country>; </corresp><corresp id="AN0002">Rita Meleddu <email>rita.meleddu@unica.it</email><institution>Department of Life and Environmental Sciences, University of Cagliari</institution>, Cagliari, <country>Italy</country></corresp></author-notes><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>20</day><month>8</month><year>2019</year></pub-date><volume>34</volume><issue>1</issue><fpage seq="150">1526</fpage><lpage>1533</lpage><history><date date-type="received"><day>18</day><month>6</month><year>2019</year></date><date date-type="rev-recd"><day>05</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>06</day><month>8</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_34_1654470.pdf"/><abstract><title>Abstract</title><p>A library of 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzene-1-sulphonamides (<bold>EMAC8002a&#x02013;m</bold>) was designed and synthesised to evaluate the effect of substituents in the positions 3 and 4 of the dihydrothiazole ring on the inhibitory potency and selectivity toward human carbonic anhydrase isoforms I, II, IX, and XII. Most of the new compounds preferentially inhibit the isoforms II and XII. Both electronic and steric features on the aryl substituent in the position 4 of the dihydrothiazole ring concur to determine the overall biological activity of these new derivatives.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Antitumour agents</kwd><kwd>carbonic anhydrase inhibitors</kwd><kwd>dihydrotiazoles</kwd><kwd>sulphonamide</kwd></kwd-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="8"/><word-count count="5202"/></counts></article-meta></front><body><sec id="s0001"><title>Introduction</title><p>1,3-thiazole and their hydrogenated analogues are important molecular subunits in diverse classes of biologically active molecules and thus can be found in several drugs approved for clinical use. Not surprisingly, this moiety has been extensively studied and both natural and synthetic thiazole derivatives are in therapeutic use or have shown potential therapeutic application toward several pathologies and targets such as bacteria<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref>, tumours<xref rid="CIT0003" ref-type="bibr"><sup>3&#x02013;6</sup></xref>, HIV-1 protease and reverse transcriptase<xref rid="CIT0007" ref-type="bibr"><sup>7&#x02013;12</sup></xref>, fungi<xref rid="CIT0013" ref-type="bibr"><sup>13&#x02013;15</sup></xref>, neurodegeneration and related pathologies<xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref>, and protozoal infections<xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref>. Recently, we reported on benzenesulphonamide dihydrothiazole derivatives as inhibitors of human carbonic anhydrase (hCA) isozymes I, II, IX, and XII19. This enzyme family catalyses the reversible hydration of carbon dioxide to bicarbonate and protons<xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref> and, therefore, plays an essential role in CO<sub>2</sub>-related metabolism and in its transportation across biological membranes<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>. Due to their simple but essential role, hCAs have been recognised as main actors in a number of physiological processes and pathologies<xref rid="CIT0022" ref-type="bibr"><sup>22&#x02013;30</sup></xref>. Not surprisingly, hCA inhibitors have been intensively studied and several are in clinical use for diverse pathologies<xref rid="CIT0031" ref-type="bibr"><sup>31&#x02013;37</sup></xref>. Although different mechanisms of inhibition of hCA have been reported (e.g. coumarins, phenols, primary amines, COOMe derivatives)<xref rid="CIT0038" ref-type="bibr"><sup>38&#x02013;42</sup></xref>, benzenesulphonamides and their isosters are the most represented molecular class of inhibitors<xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="CIT0043" ref-type="bibr"><sup>43&#x02013;48</sup></xref>. These inhibitors belong to the so called zinc binders. They bind the zinc cofactor as conjugated bases and therefore, the acidity of the sulphonamide group influences their potency. Thus, by conjugating the benzenesulphonamide group to an electron withdrawing heterocyclic ring, the activity could be favourably influenced. Moreover, the introduction of further substituents in the heterocyclic core may influence the isozyme selectivity. On these bases, and according to our previous observation<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="CIT0047" ref-type="bibr"><sup>47&#x02013;50</sup></xref>, we have synthesised and evaluated for the inhibition activity toward hCA I, II, IX, and XII isoforms a series of the 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamides (<xref ref-type="fig" rid="F0001">Figure 1</xref>).</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Carbonic anhydrase inhibitors in clinical use and previously reported EMAC derivatives: (1) acetazolamide (2) ethoxzolamide, (3) dichlorphenamide, (4) dorzolamide, (5) EMAC10020<xref rid="CIT0047" ref-type="bibr"><sup>47</sup></xref>, (6) EMAC8001<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref>, (7) EMAC8000<xref rid="CIT0048" ref-type="bibr"><sup>48</sup></xref>, (8) EMAC10153<xref rid="CIT0050" ref-type="bibr"><sup>50</sup></xref>, (9) EMAC10111<xref rid="CIT0049" ref-type="bibr"><sup>49</sup></xref>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1654470_F0001_B"/></fig></sec><sec id="s0002"><title>Methods</title><sec id="s0003"><title>Materials and apparatus</title><p>Starting materials and reagents were obtained from commercial suppliers and were used without purification. All melting points were determined on a Stuart SMP11 melting points apparatus and are uncorrected. Electron ionisation mass spectra were obtained by a Fisons QMD 1000 mass spectrometer (Danvers, MA) (70&#x02009;eV, 200&#x02009;mA, ion source temperature 200&#x02009;&#x000b0;C). Samples were directly introduced into the ion source. Melting points, yield of reactions, and analytical data of derivatives <bold>EMAC8002a&#x02013;l</bold> are reported in <xref rid="t0001" ref-type="table">Table 1</xref>.</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Chemical, analytical, and physical data of derivatives <bold>EMAC8002 a&#x02013;m</bold>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th colspan="8" align="left"><inline-graphic xlink:href="IENZ_A_1654470_ILG0001_B.gif" content-type="black-white"/><hr/></th></tr><tr><th rowspan="2" align="left">Compound</th><th rowspan="2" align="center">R</th><th rowspan="2" align="center">R.F.<xref ref-type="table-fn" rid="TF1"><sup>a</sup></xref></th><th colspan="2" align="center">C&#x02013;H&#x02013;N<hr/></th><th rowspan="2" align="center">M.P. &#x000b0;C</th><th rowspan="2" align="center">Yield %</th><th rowspan="2" align="center">Mass fragments</th></tr><tr><th align="center">Calc.</th><th align="center">Found</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>EMAC8002a</bold></td><td align="center">4-Br</td><td align="char" char=".">0.78</td><td align="left">C, 45.29; H, 3.33; N, 9.90</td><td align="left">C, 44.87; H, 3.28; N, 9.83</td><td align="char" char=".">256-259</td><td align="char" char=".">55</td><td align="center">425; 423</td></tr><tr><td align="left"><bold>EMAC8002b</bold></td><td align="center">4-Cl</td><td align="char" char=".">0.70</td><td align="left">C, 50.59; H, 3.71; N, 11.06</td><td align="left">C, 50.61; H, 3.67; N, 11.02</td><td align="char" char=".">241-242</td><td align="char" char=".">76</td><td align="char" char=".">379</td></tr><tr><td align="left"><bold>EMAC8002c</bold></td><td align="center">4-F</td><td align="char" char=".">0.63</td><td align="left">C, 52.88; H, 3.88; N, 11.56</td><td align="left">C, 52.90; H, 3.83; N, 11.51</td><td align="char" char=".">230-233</td><td align="char" char=".">58</td><td align="char" char=".">363</td></tr><tr><td align="left"><bold>EMAC8002d</bold></td><td align="center">3-NO<sub>2</sub></td><td align="char" char=".">0.74</td><td align="left">C, 49.22; H, 3.61; N, 14.35;</td><td align="left">C, 49.30; H, 3.58; N, 14.28;</td><td align="char" char=".">235-236</td><td align="char" char=".">73</td><td align="char" char=".">390</td></tr><tr><td align="left"><bold>EMAC8002e</bold></td><td align="center">2,4-Cl</td><td align="char" char=".">0.83</td><td align="left">C, 46.38; H, 3.16; N, 10.14</td><td align="left">C, 46.42; H, 3.13; N, 10.09</td><td align="char" char=".">256-257</td><td align="char" char=".">79</td><td align="char" char=".">413</td></tr><tr><td align="left"><bold>EMAC8002f</bold></td><td align="center">4-CN</td><td align="char" char=".">0.72</td><td align="left">C, 55.12; H, 3.81; N, 15.12</td><td align="left">C, 55.08; H, 3.77; N, 15.04</td><td align="char" char=".">237-238</td><td align="char" char=".">85</td><td align="char" char=".">370</td></tr><tr><td align="left"><bold>EMAC8002g</bold></td><td align="center">2,4-F</td><td align="char" char=".">0.67</td><td align="left">C, 50.38; H, 3.44; N, 11.02</td><td align="left">C, 50.31; H, 3.40; N, 10.97</td><td align="char" char=".">239-240</td><td align="char" char=".">45</td><td align="char" char=".">381</td></tr><tr><td align="left"><bold>EMAC8002h</bold></td><td align="center">4-NO<sub>2</sub></td><td align="char" char=".">0.72</td><td align="left">C, 49.22; H, 3.61; N, 14.35</td><td align="left">C, 49.00; H, 3.58; N, 14.29</td><td align="char" char=".">244-245</td><td align="char" char=".">63</td><td align="char" char=".">390</td></tr><tr><td align="left"><bold>EMAC8002i</bold></td><td align="center">4-C<sub>6</sub>H<sub>5</sub></td><td align="char" char=".">0.76</td><td align="left">C, 62.68; H, 4.54; N, 9.97</td><td align="left">C, 62.68; H, 4.52; N, 9.98</td><td align="char" char=".">254-255</td><td align="char" char=".">72</td><td align="char" char=".">421</td></tr><tr><td align="left"><bold>EMAC8002j</bold></td><td align="center">4-CH<sub>3</sub></td><td align="char" char=".">0.77</td><td align="left">C, 56.80; H, 4.77; N, 11.69</td><td align="left">C, 56. 75; H, 4.80; N, 11.61</td><td align="char" char=".">252-254</td><td align="char" char=".">67</td><td align="char" char=".">359</td></tr><tr><td align="left"><bold>EMAC8002k</bold></td><td align="center">4-OCH<sub>3</sub></td><td align="char" char=".">0.65</td><td align="left">C, 54.38; H, 4.56; N, 11.19</td><td align="left">C, 54.37; H, 4.57; N, 11.17</td><td align="char" char=".">243-244</td><td align="char" char=".">77</td><td align="char" char=".">375</td></tr><tr><td align="left"><bold>EMAC8002l</bold></td><td align="center">//</td><td align="char" char=".">0.69</td><td align="left">C, 47.84; H, 3.73; N, 11.96</td><td align="left">C, 47.80; H, 3.75; N, 11.89</td><td align="char" char=".">233-235</td><td align="char" char=".">74</td><td align="char" char=".">351</td></tr><tr><td align="left"><bold>EMAC8002m</bold></td><td align="center">H</td><td align="char" char=".">0.74</td><td align="left">C, 55.63; H, 4.38; N, 12.16</td><td align="left">C, 55.55; H, 4.34; N, 12.13</td><td align="char" char=".">252-253</td><td align="char" char=".">67</td><td align="char" char=".">345</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><label>a</label><p>R.F. values were obtained on silica gel plates using a mixture of ethyl acetate/n-hexane 2/1.</p></fn></table-wrap-foot></table-wrap><p><sup>1</sup>H-NMR (<xref rid="t0002" ref-type="table">Table 2</xref>) were registered on a Bruker AMX (300&#x02009;MHz) (chemical shifts in <italic>&#x003b4;</italic> values) or on a Unity Inova 500NB high-resolution spectrometer (Agilent Technologies, CA) (500&#x02009;MHz) All samples were measured in DMSO. Chemical shifts are reported referenced to the solvent in which they were measured. Coupling constants <italic>J</italic> are expressed in hertz (Hz). Elemental analyses were obtained on a Perkin&#x02013;Elmer 240 B microanalyser. Analytical data of the synthesised compounds are in agreement within &#x000b1; 0.4% of the theoretical values. TLC chromatography was performed using silica gel plates (Merck F 254), spots were visualised by UV light.</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>1H NMR data of derivatives <bold>EMAC8002a&#x02013;m</bold>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Compound</th><th align="center"><sup>1</sup>H NMR &#x003b4; (ppm)</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>EMAC8002a</bold></td><td align="left"><sup>1</sup>H-NMR: (300&#x02009;MHz, DMSO) 3.57 (3H, s, CH<sub>3</sub>), 7.10 (1H, s, CH thiazole), 7.45 (2H, s, NH<sub>2</sub>, D<sub>2</sub>O), 7.54 (2H, d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, CH Ar), 7.61 (2H, d, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;Hz, CH Ar), 7.78 (2H, d, <italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, CH Ar), 7.95 (2H, d, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;Hz, CH Ar)</td></tr><tr><td align="left"><bold>EMAC8002b</bold></td><td align="left"><sup>1</sup>H-NMR: (300&#x02009;MHz, DMSO) 3.46 (3H, s, CH<sub>3</sub>), 6.83 (1H, s, CH thiazole), 7.36 (2H, s, NH<sub>2</sub>, D<sub>2</sub>O), 7.44 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.4&#x02009;Hz, CH Ar), 7.58 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;Hz, CH Ar), 7.63 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.4&#x02009;Hz, CH Ar), 7.88 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, CH Ar)</td></tr><tr><td align="left"><bold>EMAC8002c</bold></td><td align="left"><sup>1</sup>H-NMR: (300&#x02009;MHz, DMSO) 3.65 (3H, s, CH<sub>3</sub>), 7.01 (1H, s, CH thiazole), 7.50 (2H, t, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, CH Ar), 7.56 (2H, s, NH<sub>2</sub>, D<sub>2</sub>O), 7.67 (2H, d, <italic>J</italic>: 8.7 CH Ar), 7.74 (2H, dd, <italic>J</italic>H-H: 8.5, <italic>J</italic>H-F: 5.5, CH Ar), 8.02 (2H, d, <italic>J</italic>: 9.0, CH Ar)</td></tr><tr><td align="left"><bold>EMAC8002d</bold></td><td align="left"><sup>1</sup>H-NMR: (300&#x02009;MHz, DMSO) NH<sub>2</sub> not detected, 3.34 (3H, s, CH<sub>3</sub>), 6.59 (1H, s, CH thiazole), 7.18 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, CH Ar), 7.24 (1H, s, CH Ar), 7.78 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, CH Ar), 7.83 (1H, d, <italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, CH Ar), 8.01 (1H, d, <italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, CH Ar), 8.34 (1H, d, <italic>J</italic>&#x02009;=&#x02009;2.0&#x02009;Hz, CH Ar)</td></tr><tr><td align="left"><bold>EMAC8002e</bold></td><td align="left"><sup>1</sup>H-NMR: (500&#x02009;MHz, DMSO) 3.25 (3H, s, CH<sub>3</sub>), 6.68 (1H, s, CH thiazole), 7.29 (2H, s, NH<sub>2</sub>, D<sub>2</sub>O), 7.34 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8&#x02009;Hz, CH Ar), 7.59 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8&#x02009;Hz, CH Ar), 7.63 (1H, dd, J&#x02009;=&#x02009;8.5, 2&#x02009;Hz), 7.83 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, CH Ar), 7.88 (1H, d, <italic>J</italic>&#x02009;=&#x02009;2&#x02009;Hz, CH Ar)</td></tr><tr><td align="left"><bold>EMAC8002f</bold></td><td align="left"><sup>1</sup>H-NMR: (300&#x02009;MHz, DMSO) 3.46 (3H, s, CH<sub>3</sub>), 6.83 (1H, s, CH thiazole), 7.36 (2H, s, NH<sub>2</sub>, D<sub>2</sub>O), 7.44 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.4&#x02009;Hz, CH Ar), 7.58 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;Hz, CH Ar), 7.63 (2H, dd, <italic>J</italic>&#x02009;=&#x02009;8.4&#x02009;Hz, CH Ar), 7.88 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, CH Ar)</td></tr><tr><td align="left"><bold>EMAC8002g</bold></td><td align="left"><sup>1</sup>H-NMR: (300&#x02009;MHz, DMSO) 3.55 (3H, s, CH<sub>3</sub>), 7.13 (1H, s, CH thiazole), 7.34 (1H, td, <italic>J</italic>&#x02009;=&#x02009;8.4, 1.5&#x02009;Hz, CH Ar), 7.45 (2H, s, NH<sub>2</sub>, D<sub>2</sub>O), 7.67-7.53 (4H, m, CH Ar), 7.93 (2H, d, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, CH Ar)</td></tr><tr><td align="left"><bold>EMAC8002h</bold></td><td align="left">1H-NMR: (300&#x02009;MHz, DMSO) 3.36 (3H, s, CH<sub>3</sub>), 6.61 (1H, s, CH thiazole), 7.17 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, CH Ar), 7.25 (2H, s, NH<sub>2</sub>, D<sub>2</sub>O), 7.79 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, CH Ar), 7.83 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;Hz, CH Ar), 8.33 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, CH Ar)</td></tr><tr><td align="left"><bold>EMAC8002i</bold></td><td align="left"><sup>1</sup>H-NMR: (500&#x02009;MHz, DMSO) 3.59 (3H, s, CH<sub>3</sub>), 7.0 (1H, s, CH thiazole), 7.40 (2H, s, NH<sub>2</sub>)<sub>,</sub> 7.43 (1H, m, CH Ar), 7.52 (2H, m, CH Ar), 7.56 (2H, d, J&#x02009;=&#x02009;8&#x02009;Hz, CH Ar), 7.66 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8&#x02009;Hz, CH Ar), 7.75 (2H, m,CH Ar), 7.87 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, CH Ar), 7.93 (2H, d, J&#x02009;=&#x02009;8.5&#x02009;Hz)</td></tr><tr><td align="left"><bold>EMAC8002j</bold></td><td align="left"><sup>1</sup>H-NMR: (300&#x02009;MHz, DMSO) 2.40 (3H, s, CH<sub>3</sub>), 3.53 (3H, s, CH<sub>3</sub>), 6.91 (1H, s, CH thiazole), 7.46-7.36 (6H, m, CH Ar), 7.55 (2H, s, NH<sub>2</sub>, D<sub>2</sub>O), 7.92 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, CH Ar)</td></tr><tr><td align="left"><bold>EMAC8002k</bold></td><td align="left"><sup>1</sup>H-NMR: (300&#x02009;MHz, DMSO) 3.64 (3H, s, CH<sub>3</sub>), 3.96 (3H, s, OCH<sub>3</sub>), 6.98 (1H, s, CH thiazole), 7.23 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, CH Ar), 7.54 (2H, s, NH<sub>2</sub>, D<sub>2</sub>O), 7.63-7.60 (4H, m, CH Ar), 8.04 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.1&#x02009;Hz, CH Ar)</td></tr><tr><td align="left"><bold>EMAC8002l</bold></td><td align="left"><sup>1</sup>H-NMR: (300&#x02009;MHz, DMSO) 3.61 (3H, s, CH<sub>3</sub>), 7.15 (1H, s, CH thiazole), 7.48 (2H, s, NH<sub>2</sub>, D<sub>2</sub>O), 7.59 (5H, m, CH Ar), 7.67 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, CH Ar), 7.97 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, CH Ar)</td></tr><tr><td align="left"><bold>EMAC8002m</bold></td><td align="left"><sup>1</sup>H-NMR: (300&#x02009;MHz, DMSO) 3.61 (3H, s, CH<sub>3</sub>), 7.15 (1H, s, CH thiazole), 7.48 (2H, s, NH<sub>2</sub>, D<sub>2</sub>O), 7.59 (5H, m, CH Ar), 7.67 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, CH Ar), 7.97 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, CH Ar)</td></tr></tbody></table></table-wrap></sec></sec><sec id="s0004"><title>General procedure for the synthesis of compound EMAC8002a&#x02013;m</title><sec id="s0005"><title>Synthesis of 1-methyl-3&#x02013;(4-sulfamoylethyl)thiourea</title><p>To an ethanolic solution of 4-aminobenzenesulphonamide (1 eq), methyl isothiocyanate (2 eq) was added dropwise. The mixture was heated under reflux until the completion of the reaction (10&#x02009;h). The progress of the reaction was monitored by TLC (ethyl acetate/n-hexane 2/1). Then the reaction was cooled overnight in the fridge. A precipitate was formed which was collected by filtration under vacuum and crystallised from ethanol to afford the desired product.</p></sec><sec id="s0006"><title>Synthesis of 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamide</title><p>A mixture of 1-methyl-3&#x02013;(4-sulfamoylphenyl)thiourea (1 eq) and &#x003b1;-halogenoketone (1 eq) was reacted in ethanol solution. Different reaction conditions have been employed. Thus, while in the presence of &#x003b1;-bromoketones the reaction temperature was kept between 30 and 50&#x02009;&#x000b0;C, refluxing conditions were used when &#x003b1;-chloroketones were reacted. The mixture was reacted until completion (TLC, ethyl acetate/n-hexane 2/1). By cooling to room temperature, a precipitate was formed. The crude product was filtered and crystallised from the appropriate solvent. Analytical and spectral data of compounds <bold>EMAC8002a&#x02013;m</bold> are reported in <xref rid="t0001 t0002" ref-type="table">Tables 1 and 2</xref>.</p></sec></sec><sec id="s0007"><title>Molecular modelling</title><p>The new ligand <bold>EMAC8002i</bold> was built by means of Maestro GUI<xref rid="CIT0051" ref-type="bibr"><sup>51</sup></xref> in E configuration. Then a conformational search analysis was performed using MCMM method allowing 5000 iterations in implicit solvent<xref rid="CIT0052" ref-type="bibr"><sup>52</sup></xref>.</p><p>Docking experiments were performed by means of Glide Quantum-Mechanical Polarised Docking<xref rid="CIT0053" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="CIT0054" ref-type="bibr"><sup>54</sup></xref>. The crystallographic model with the best resolution was considered (pdb code 5MSA, 1.2&#x02009;&#x000c5;). The protein was prepared with Preparation Wizard protocol. The Grid box was centred on the co-crystallised ligand and all parameters were set up as default.</p><p>The best pose complex was then minimised to consider the induced fit phenomena and used to analyse the ligand-binding mode. 10,000 steps of the Polak-Ribier conjugate gradient (PRCG) minimisation method were conducted on the top ranked theoretical complex using OPLS_2005 force field<xref rid="CIT0055" ref-type="bibr"><sup>55</sup></xref>.</p><p>The optimisation process was performed up to the derivative convergence criterion equal to 0.05&#x02009;kcal/(mol*&#x000c5;)<sup>&#x02212;1</sup>.</p></sec><sec id="s0008"><title>Biological activity</title><sec id="s0009"><title>Carbonic anhydrase inhibition assay</title><p>The purification of cytosolic CA isoenzymes (CA I and CA II) was previously described with a simple one-step method by a Sepharose-4B-L tyrosine-sulphanilamide affinity chromatography<xref rid="CIT0056" ref-type="bibr"><sup>56</sup></xref>.</p><p>The protein quantity in the column effluents was determined spectrophotometrically at 280&#x02009;nm. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was applied with a Bio-Rad Mini Gel system Mini-PROTEINVR system (Hercules, CA), Bio-Rad Laboratories, Inc., China after purification of both CA isoenzymes. Briefly, it was performed in acrylamide for the running (10%) and the stacking gel (3%) contained SDS (0.1%), respectively. Activities of CA isoenzymes were determined according to a method by Verporte et&#x000a0;al.<xref rid="CIT0057" ref-type="bibr"><sup>57</sup></xref>. The increase in absorbance of the reaction medium was spectrophotometrically recorded at 348&#x02009;nm. Also, the quantity of protein was determined at 595&#x02009;nm according to the Bradford method<xref rid="CIT0058" ref-type="bibr"><sup>58</sup></xref>. Bovine serum albumin was used as standard protein. The IC<sub>50</sub> values were obtained from activity (%) versus compounds plots<xref rid="CIT0059" ref-type="bibr"><sup>59</sup></xref>. For calculation of <italic>K</italic><sub>I</sub> values, three different concentrations were used. The Lineweaver&#x02013;Burk curves were drawn and calculations were realised<xref rid="CIT0059" ref-type="bibr"><sup>59</sup></xref>. The biological data are reported in <xref rid="t0003" ref-type="table">Table 3</xref>.</p><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Inhibition data towards hCA I, II, IX, and XII of compounds <bold>EMAC8002 a&#x02013;m</bold>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th colspan="6" align="left"><inline-graphic xlink:href="IENZ_A_1654470_ILG0002_B.gif" content-type="black-white"/><hr/></th></tr><tr><th colspan="2" align="left">&#x000a0;</th><th colspan="4" align="center"><italic>K</italic><sub>i</sub> (nM)<hr/></th></tr><tr><th align="left">Compound</th><th align="center">R</th><th align="center">hCA I</th><th align="center">hCA II</th><th align="center">hCA IX</th><th align="center">hCA XII</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>EMAC8002a</bold></td><td align="left">4-Br</td><td align="char" char=".">4457</td><td align="char" char=".">45.8</td><td align="char" char=".">58.1</td><td align="char" char=".">778</td></tr><tr><td align="left"><bold>EMAC8002b</bold></td><td align="left">4-Cl</td><td align="char" char=".">1548</td><td align="char" char=".">13.1</td><td align="char" char=".">1213</td><td align="char" char=".">97.9</td></tr><tr><td align="left"><bold>EMAC8002c</bold></td><td align="left">4-F</td><td align="char" char=".">4845</td><td align="char" char=".">5.3</td><td align="char" char=".">2482</td><td align="char" char=".">40.0</td></tr><tr><td align="left"><bold>EMAC8002d</bold></td><td align="left">3-NO<sub>2</sub></td><td align="char" char=".">2456</td><td align="char" char=".">17.8</td><td align="char" char=".">1821</td><td align="char" char=".">271</td></tr><tr><td align="left"><bold>EMAC8002e</bold></td><td align="left">2,4-Cl</td><td align="char" char=".">&#x0003e;10,000</td><td align="char" char=".">398</td><td align="char" char=".">1605</td><td align="char" char=".">10.5</td></tr><tr><td align="left"><bold>EMAC8002f</bold></td><td align="left">4-CN</td><td align="char" char=".">2650</td><td align="char" char=".">17.9</td><td align="char" char=".">2064</td><td align="char" char=".">94.7</td></tr><tr><td align="left"><bold>EMAC8002g</bold></td><td align="left">2,4-F</td><td align="char" char=".">&#x0003e;10,000</td><td align="char" char=".">37.7</td><td align="char" char=".">1648</td><td align="char" char=".">9.0</td></tr><tr><td align="left"><bold>EMAC8002h</bold></td><td align="left">4-NO<sub>2</sub></td><td align="char" char=".">2239</td><td align="char" char=".">19.9</td><td align="char" char=".">142</td><td align="char" char=".">9.5</td></tr><tr><td align="left"><bold>EMAC8002i</bold></td><td align="left">4-C<sub>6</sub>H<sub>5</sub></td><td align="char" char=".">8910</td><td align="char" char=".">503</td><td align="char" char=".">1389</td><td align="char" char=".">9.5</td></tr><tr><td align="left"><bold>EMAC8002j</bold></td><td align="left">4-CH<sub>3</sub></td><td align="char" char=".">2603</td><td align="char" char=".">4.5</td><td align="char" char=".">23.3</td><td align="char" char=".">3.1</td></tr><tr><td align="left"><bold>EMAC8002k</bold></td><td align="left">4-OCH<sub>3</sub></td><td align="char" char=".">5580</td><td align="char" char=".">3.8</td><td align="char" char=".">25.4</td><td align="char" char=".">4.6</td></tr><tr><td align="left"><bold>EMAC8002l</bold></td><td align="left">//</td><td align="char" char=".">1650</td><td align="char" char=".">30.3</td><td align="char" char=".">1874</td><td align="char" char=".">36.9</td></tr><tr><td align="left"><bold>EMAC8002m</bold></td><td align="left">H</td><td align="char" char=".">2305</td><td align="char" char=".">5.3</td><td align="char" char=".">620</td><td align="char" char=".">9.4</td></tr><tr><td align="left">AAZ</td><td align="left">//</td><td align="char" char=".">250</td><td align="char" char=".">12</td><td align="char" char=".">25</td><td align="char" char=".">5.7</td></tr></tbody></table></table-wrap></sec></sec><sec id="s0010"><title>Results and discussion</title><p>As a continuation of our ongoing research in the field of carbonic anhydrase and anticancer agents<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="CIT0047" ref-type="bibr"><sup>47&#x02013;49</sup></xref><sup>,</sup><xref rid="CIT0060" ref-type="bibr"><sup>60</sup></xref>, we have synthesised a new series of 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamides, namely compounds <bold>EMAC8002a&#x02013;m</bold>, to evaluate their activity and selectivity toward CA isozymes and to gain information on the structure&#x02013;activity relationships of these derivatives. All the synthesised derivatives are characterised by the presence of a benzenesulphonamide moiety as zinc binder group, conjugated with the position 2 of a dihydrothiazole heterocyclic core. A methyl substituent is always present on the heterocyclic nitrogen atom, while a differently substituted aromatic ring occupies the position 4.</p><p>The synthetic procedure to obtain compounds <bold>EMAC8002a&#x02013;m</bold> is depicted in <xref ref-type="scheme" rid="SCH0001">Scheme 1</xref>. Briefly, it consists of two steps: the synthesis of the 3&#x02010;methyl&#x02010;1&#x02010;(4&#x02010;sulfamoylphenyl)thiourea (1) by reaction of the 4-aminobenzensufonamide with methyl isocyanate. The second step is the formation of the 4-aryl dihydrothiazole nucleus. It was accomplished by reacting 1 with the appropriate &#x003b1;-halogenoketone in ethanol solution. <bold>EMAC8002a&#x02013;m</bold> were characterised by means of analytical and spectroscopic methods (<xref rid="t0001" ref-type="table">Tables 1</xref> and <xref rid="t0002" ref-type="table">2</xref>) and then submitted to enzymatic evaluation toward hCA I, II, IX, and XII.</p><fig id="SCH0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Synthetic pathway to compounds <bold>EMAC8002a&#x02013;m</bold>. Reagents and conditions: (i) ethanol, methylisothiocyanate; (ii) ethanol, &#x003b1;-halogenoarylketone.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1654470_SCH0001_B"/></fig><p>The results are summarised in <xref rid="t0003" ref-type="table">Table 3</xref>. Accordingly with our previous observations with similar derivatives, none of the <bold>EMAC8002</bold> compounds was active toward hCA I isozyme. On the contrary, when isozymes II, IX, and XII are investigated, some consideration regarding the structure&#x02013;activity relationships could be done. When compounds <bold>EMAC8002</bold> are tested on hCA II, the introduction of a halogen atom, in position 4 of the phenyl moiety, in position 4 of the dihydrothiazole ring, appeared beneficial for the activity. However, the larger is the atomic radius of the halogen, the lower the activity. So far, the <italic>K</italic><sub>i</sub> values are in the following order: 4-F (<bold>EMAC8002c</bold>) 5.3&#x02009;nM &#x0003c;4-Cl (<bold>EMAC8002b</bold>) 13.1&#x02009;nM &#x0003c;4-Br (<bold>EMAC8002a</bold>) 45.8&#x02009;nM. A similar behaviour was observed in the case of hCAXII: 4-F (<bold>EMAC8002c</bold>) 5.3&#x02009;nM &#x0003c;4-Cl (<bold>EMAC8002b</bold>) 13.1&#x02009;nM &#x0003c;4-Br (<bold>EMAC8002a</bold>) 45.8&#x02009;nM. On the contrary, when the same compounds were evaluated on hCA IX, a totally reversed trend was observed. In fact, the larger is the halogen atom the higher the activity. Accordingly, the <italic>K</italic><sub>i</sub> values are 4-F (<bold>EMAC8002c</bold>) 2482&#x02009;nM &#x0003e; 4-Cl (<bold>EMAC8002b</bold>) 1213&#x02009;nM &#x0003e; 4-Br (<bold>EMAC8002a</bold>) 58.1&#x02009;nM. The introduction of a second halogen atom in the position 2 of the phenyl ring is beneficial only for the activity toward the hCA XII isoform. Thus, in the case of compounds <bold>EMA8002e</bold> (2,4-Cl) and <bold>EMAC8002g</bold> (2,4-F) the Ki values are 10.5 and 9.0&#x02009;nM, respectively. Accordingly, when the 4-Cl derivative (<bold>EMAC8002b)</bold> is compared with the 2,4-diCl one (<bold>EMAC8002e),</bold> a 9-fold gain in potency toward the hCA XII isozyme was observed. Similarly, a 4-fold increase in potency toward hCA XII was observed when 4-F (<bold>EMAC8002c</bold>) and 2,4-diF (<bold>EMAC8002g</bold>) are compared. On the contrary, the inverse was observed when hCA II isozyme is considered. A decrease in the activity of 7 folds was observed when 2,4-diF (<bold>EMAC8002g</bold>) was compared with 4-F (<bold>EMAC8002c</bold>). Analogously a decrease of the inhibition potency of 30 folds was measured when 2,4-diCl (<bold>EMAC8002e</bold>) was compared with 4-Cl (<bold>EMAC8002b</bold>). On these bases, we can summarise that by introducing specific halogen atoms in specific positions of the 4-phenyl ring, it is possible to modulate the activity toward different hCA isozymes. The introduction of a nitro group is tolerated both in the 3 and 4 position of the phenyl ring when hCA II is considered. On the contrary, when the activity on hCA XII is measured, the introduction of the nitro group is only tolerated in the 4 position. The introduction of electron-donating groups such as methyl or methoxy, as in compounds <bold>EMAC8002j</bold> and <bold>EMAC8002k</bold>, respectively, led to most active compounds when hCA II, IX, and XII are considered. Unfortunately, none of the two substitutions led to selective compounds. The presence of a nitrile in the position 4 as in the case of compound <bold>EMAC8002f</bold>, is generally detrimental for the activity, but for hCAII, where this substitution is tolerated. By introducing a biphenyl group in the position 4 of the dihydrothiazole, the most selective compound toward hCA XII (<bold>EMAC8002i</bold>) was obtained, with a selective index hCA II/hCA XII higher than 52. When compared with 4-phenyldihydrothiazole (<bold>EMAC8002m</bold>), the isosteric introduction of a thiophene-2-yl moiety in the position 4 of the dihydrothiazole (<bold>EMAC8002l</bold>) was beneficial only for the activity toward hCA I, although with high values of Ki.</p><p>These results, together with our previous findings, indicate that the 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamide scaffold could be rationally and efficiently decorated in order to achieve potent and selective hCA inhibitors.</p><p>The possible formation of both E and Z diastereoisomers along the C=N double bond was investigated by 2D NMR experiments. To this end, the ROESY spectrum of the most interesting compound of the series <bold>EMAC8002i</bold> was recorded (<xref ref-type="fig" rid="F0002">Figure 2</xref>). This derivative showed good selectivity toward hCA XII and inhibitory activity toward this enzyme in the low nM range. ROESY cross-peak from the methyl group at &#x003b4;<sub>H</sub> 3.59 (3H, s) to the aromatic protons H-2 and H-3 at &#x003b4;<sub>H</sub> 7.56 (2H, <italic>d</italic>, <italic>J</italic>&#x02009;=&#x02009;8&#x02009;Hz) permitted to assign the configuration around the double bond as E. In fact, examination of a molecular model confirms that, in the case of (Z) configuration, H-2 and H-3 aromatic protons would be too far to the methyl group and correlation should not be observed. Analogous experiments were performed along the full series of compounds and, as expected, the (E) configuration was assigned to all derivatives.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>(a) ROESY spectrum of compound <bold>EMAC8002i</bold>; (b) Partial ROESY spectrum of compound <bold>EMAC8002i</bold>.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1654470_F0002_C"/></fig><p>In order to predict the binding mode of compound <bold>EMAC8002i</bold>, a molecular docking experiment was performed. The most selective was well docked into the catalytic site of CA XII with binding energies of &#x02212;10.194&#x02009;kcal/mol. The complex has been energy minimised and the putative binding mode is depicted in <xref ref-type="fig" rid="F0003">Figure 3</xref>.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Three-dimensional representation of the putative binding mode as obtained by docking experiments of: (a) <bold>EMAC8002-i</bold> and (b) relative 2D representation of the complex stabilising interactions with the residues of the binding site.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1654470_F0003_C"/></fig><p>The ligand well fit into the binding pocket. The benzenesulphonamide moiety tightly interacts with the deep cavity and the Zn (II) ion, being stabilised by the metal chelation and an array of hydrogen bonds with the residues around the ion: Thr198, Thr199, and His117. Furthermore, the nitrogen atom of the aminobenzenesulphonamide moiety interacts with Gln89. Moreover, the substituent in the position 4 of the thiazolino portion interacts with the external part of the cavity. The analysis of the putative binding mode highlighted the presence of extra space in correspondence of the N methyl substituent which will be exploited to increase the ligand complementarity and probably its activity and selectivity.</p></sec><sec id="s0011"><title>Conclusions</title><p>We have designed and synthesised a series of 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamides and evaluate their activity on hCA I, II, IX, and XII isozymes. While these derivatives were weak inhibitors of the hCA I isoform, interestingly, the nature and substitution pattern of the aromatic group in the position 4 of the dihydrothiazole core was relevant for the activity and the selectivity between the hCA II and XII isoforms. Nevertheless, we observed that the introduction of a 4-methylphenyl or a 4-methoxyphenyl moiety in the position 4 of the dihydrothiazole ring is beneficial for the activity toward hCA II, IX, and XII isozymes. These data prompted us to further investigate on these scaffolds in order to optimise both the activity and the isozyme selectivity.</p></sec></body><back><sec><title>Acknowledgements</title><p>The authors wish to acknowledge the &#x0201c;Ufficio Valorizzazione dei Risultati della Ricerca&#x0201d; of Sardegna Ricerche Technological Park, Pula (CA) &#x02013; Italy. The authors also thank the COST action CA15135 (Multitarget Paradigm for Innovative Ligand Identification in the Drug Discovery Process MuTaLig) for support. </p></sec><sec id="s0012"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lott</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Bergeim</surname><given-names>FH</given-names></name></person-group>
<article-title>2-(p-Aminobenzenesulfonamido)-thiazole: a new chemotherapeutic agent</article-title>. <source>J Am Chem Soc</source>
<year>1939</year>;<volume>61</volume>:<fpage>3593</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ball</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Geddes</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Davey</surname><given-names>PG</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study</article-title>. <source>Lancet</source>
<year>1980</year>;<volume>1</volume>:<fpage>620</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">6102627</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oslob</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Allen</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Baskaran</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of a potent and selective aurora kinase inhibitor</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2008</year>;<volume>18</volume>:<fpage>4880</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">18678489</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Claussen</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>EC</given-names></name></person-group>
<article-title>Nucleic acid recognition by metal complexes of bleomycin</article-title>. <source>Chem Rev</source>
<year>1999</year>;<volume>99</volume>:<fpage>2797</fpage>&#x02013;<lpage>816</lpage>.<pub-id pub-id-type="pmid">11749501</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tricot</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Jayaram</surname><given-names>HN</given-names></name>, <name name-style="western"><surname>Weber</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Tiazofurin: biological effects and clinical uses</article-title>. <source>Int J Cell Clon</source>
<year>1990</year>;<volume>8</volume>:<fpage>161</fpage>&#x02013;<lpage>70</lpage>.</mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hara</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Asano</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kawamoto</surname><given-names>I</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Leinamycin, a new antitumor antibiotic from streptomyces: producing organism, fermentation and isolation</article-title>. <source>J Antibiot</source>
<year>1989</year>;<volume>42</volume>:<fpage>1768</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">2621160</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kempf</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Marsh</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Denissen</surname><given-names>JF</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>1995</year>;<volume>92</volume>:<fpage>2484</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">7708670</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meleddu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Distinto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Corona</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Isatin thiazoline hybrids as dual inhibitors of HIV-1 reverse transcriptase</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2017</year>;<volume>32</volume>:<fpage>130</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">27766892</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meleddu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Distinto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Corona</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase</article-title>. <source>Eur J Med Chem</source>
<year>2015</year>;<volume>93</volume>:<fpage>452</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">25728026</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corona</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Meleddu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Esposito</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Ribonuclease H/DNA polymerase HIV-1 reverse transcriptase dual inhibitor: mechanistic studies on the allosteric mode of action of isatin-based compound RMNC6</article-title>. <source>PLoS One</source>
<year>2016</year>;<volume>11</volume>:<fpage>e0147225</fpage>.<pub-id pub-id-type="pmid">26800261</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Distinto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Maccioni</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Meleddu</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Molecular aspects of the RT/drug interactions. perspective of dual inhibitors</article-title>. <source>Curr Pharm Design</source>
<year>2013</year>;<volume>19</volume>:<fpage>1850</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Distinto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Esposito</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Kirchmair</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach</article-title>. <source>Eur J Med Chem</source>
<year>2012</year>;<volume>50</volume>:<fpage>216</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">22361685</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meleddu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Distinto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Corona</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Exploring the thiazole scaffold for the identification of new agents for the treatment of fluconazole resistant Candida</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>1672</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">26745285</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ojika</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tsukamoto</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cystothiazoles A and B, new bithiazole-type antibiotics from the myxobacterium <italic>Cystobacter fuscus</italic></article-title>. <source>J Antibiot</source>
<year>1998</year>;<volume>51</volume>:<fpage>275</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">9589062</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marquez</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Watts</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Yokochi</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly</article-title>. <source>J Nat Prod</source>
<year>2002</year>;<volume>65</volume>:<fpage>866</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">12088429</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa</surname><given-names>FH</given-names></name>, <name name-style="western"><surname>Rosso</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Maultasch</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Depression in Parkinson's disease: diagnosis and treatment</article-title>. <source>Arquivos de Neuro-Psiquiatria</source>
<year>2012</year>;<volume>70</volume>:<fpage>617</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">22899034</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chimenti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Maccioni</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Secci</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones</article-title>. <source>J Med Chem</source>
<year>2008</year>;<volume>51</volume>:<fpage>4874</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">18666768</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willcox</surname><given-names>RR</given-names></name></person-group>
<article-title>Treatment of vaginal trichomoniasis with aminitrozole and trichomycin given orally</article-title>. <source>Gynaecologia</source>
<year>1960</year>;<volume>149</volume>:<fpage>122</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">13844789</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domsic</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Avvaru</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>CU</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Entrapment of carbon dioxide in the active site of carbonic anhydrase II</article-title>. <source>J Biol Chem</source>
<year>2008</year>;<volume>283</volume>:<fpage>30766</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">18768466</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boron</surname><given-names>WF</given-names></name></person-group>
<article-title>Evaluating the role of carbonic anhydrases in the transport of HCO3&#x02212;-related species</article-title>. <source>Biochimica et Biophysica Acta</source>
<year>2010</year>;<volume>1804</volume>:<fpage>410</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">19879980</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geers</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gros</surname><given-names>G</given-names></name></person-group>
<article-title>Carbon dioxide transport and carbonic anhydrase in blood and muscle</article-title>. <source>Physiol Rev</source>
<year>2000</year>;<volume>80</volume>:<fpage>681</fpage>&#x02013;<lpage>715</lpage>.<pub-id pub-id-type="pmid">10747205</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horie</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kawakami</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fujita</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Exosomes expressing carbonic anhydrase 9 promote angiogenesis</article-title>. <source>Biochem Biophys Res Commun</source>
<year>2017</year>;<volume>492</volume>:<fpage>356</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">28851650</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Structure and function of carbonic anhydrases</article-title>. <source>Biochem J</source>
<year>2016</year>;<volume>473</volume>:<fpage>2023</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">27407171</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McIntyre</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hulikova</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ledaki</surname><given-names>I</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Disrupting hypoxia-induced bicarbonate transport acidifies tumor cells and suppresses tumor growth</article-title>. <source>Cancer Res</source>
<year>2016</year>;<volume>76</volume>:<fpage>3744</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">27197160</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>XL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Correlation between carbonic anhydrase IX (CA-9), XII (CA-12) and hypoxia inducible factor-2&#x003b1; (HIF-2&#x003b1;) in breast cancer</article-title>. <source>Neoplasma</source>
<year>2015</year>;<volume>62</volume>:<fpage>456</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">25866226</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imtaiyaz Hassan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shajee</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Waheed</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structure, function and applications of carbonic anhydrase isozymes</article-title>. <source>Bioorg Med Chem</source>
<year>2013</year>;<volume>21</volume>:<fpage>1570</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">22607884</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Inhibition of carbonic anhydrase IX as a novel anticancer mechanism</article-title>. <source>World J Clin Oncol</source>
<year>2012</year>;<volume>3</volume>:<fpage>98</fpage>&#x02013;<lpage>103</lpage>.<pub-id pub-id-type="pmid">22787577</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neri</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Interfering with pH regulation in tumours as a therapeutic strategy</article-title>. <source>Nat Rev Drug Discov</source>
<year>2011</year>;<volume>10</volume>:<fpage>767</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">21921921</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swietach</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Vaughan-Jones</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>AL</given-names></name></person-group>
<article-title>Regulation of tumor pH and the role of carbonic anhydrase 9</article-title>. <source>Cancer Metast Rev</source>
<year>2007</year>;<volume>26</volume>:<fpage>299</fpage>&#x02013;<lpage>310</lpage>.</mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Mokhtari</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase II mediates malignant behavior of pulmonary neuroendocrine tumors</article-title>. <source>Am J Respir Cell Mol Biol</source>
<year>2015</year>;<volume>52</volume>:<fpage>183</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">25019941</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meleddu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Maccioni</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Distinto</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>New 4-[(3-cyclohexyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzene-1-sulphonamides, synthesis and inhibitory activity toward carbonic anhydrase I, II, IX, XII</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2015</year>;<volume>25</volume>:<fpage>3281</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">26073006</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Fares</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ceruso</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Amido/ureidosubstituted benzenesulphonamides-isatin conjugates as low nanomolar/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII</article-title>. <source>Eur J Med Chem</source>
<year>2016</year>;<volume>110</volume>:<fpage>259</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">26840366</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ceruso</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bragagni</surname><given-names>M</given-names></name>, <name name-style="western"><surname>AlOthman</surname><given-names>Z</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>New series of sulphonamides containing amino acid moiety act as effective and selective inhibitors of tumor-associated carbonic anhydrase XII</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2015</year>;<volume>30</volume>:<fpage>430</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">25089707</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Structure-based drug discovery of carbonic anhydrase inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2012</year>;<volume>27</volume>:<fpage>759</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">22468747</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Carbonic anhydrases: novel therapeutic applications for inhibitors and activators</article-title>. <source>Nat Rev Drug Discov</source>
<year>2008</year>;<volume>7</volume>:<fpage>168</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">18167490</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity</article-title>. <source>Expert Opin Ther Pat</source>
<year>2003</year>;<volume>13</volume>:<fpage>1545</fpage>&#x02013;<lpage>50</lpage>.</mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picard</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Deshaies</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lalonde</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats</article-title>. <source>Obes. Res</source>
<year>2000</year>;<volume>8</volume>:<fpage>656</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">11225714</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maresca</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Temperini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Pochet</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins</article-title>. <source>J Med Chem</source>
<year>2010</year>;<volume>53</volume>:<fpage>335</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">19911821</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maresca</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Temperini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Vu</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors</article-title>. <source>J Am Chem Soc</source>
<year>2009</year>;<volume>131</volume>:<fpage>3057</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">19206230</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>How many carbonic anhydrase inhibition mechanisms exist?</article-title>
<source>J Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>345</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">26619898</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Simone</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Alterio</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors</article-title>. <source>Expert Opin Drug Discov</source>
<year>2013</year>;<volume>8</volume>:<fpage>793</fpage>&#x02013;<lpage>810</lpage>.<pub-id pub-id-type="pmid">23627619</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alterio</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Di Fiore</surname><given-names>A</given-names></name>, <name name-style="western"><surname>D'Ambrosio</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?</article-title>
<source>Chem Rev</source>
<year>2012</year>;<volume>112</volume>:<fpage>4421</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">22607219</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pala</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Micheletto</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sechi</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibition with benzenesulphonamides and tetrafluorobenzenesulphonamides obtained via click chemistry</article-title>. <source>ACS Med Chem Lett</source>
<year>2014</year>;<volume>5</volume>:<fpage>927</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">25147616</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suthar</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Bansal</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lohan</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design and synthesis of novel 4-(4-oxo-2-arylthiazolidin-3-yl)benzenesulphonamides as selective inhibitors of carbonic anhydrase IX over I and II with potential anticancer activity</article-title>. <source>Eur J Med Chem</source>
<year>2013</year>;<volume>66</volume>:<fpage>372</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">23827177</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guzel-Akdemir</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Akdemir</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Karali</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of novel isatin-based sulphonamides with potent and selective inhibition of the tumor-associated carbonic anhydrase isoforms IX and XII</article-title>. <source>Org Biomol Chem</source>
<year>2015</year>;<volume>13</volume>:<fpage>6493</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25967275</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Abou-Seri</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Tanc</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Isatin-pyrazole benzenesulphonamide hybrids potently inhibit tumor-associated carbonic anhydrase isoforms IX and XII</article-title>. <source>Eur J Med Chem</source>
<year>2015</year>;<volume>103</volume>:<fpage>583</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">26408817</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melis</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Meleddu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Angeli</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Isatin: a privileged scaffold for the design of carbonic anhydrase inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2017</year>;<volume>32</volume>:<fpage>68</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">27775452</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianco</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Meleddu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Distinto</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>N-Acylbenzenesulphonamide dihydro-1,3,4-oxadiazole hybrids: seeking selectivity toward carbonic anhydrase isoforms</article-title>. <source>ACS Med Chem Lett</source>
<year>2017</year>;<volume>8</volume>:<fpage>792</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">28835790</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meleddu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Distinto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cottiglia</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Tuning the dual inhibition of carbonic anhydrase and cyclooxygenase by dihydrothiazole benzensulphonamides</article-title>. <source>ACS Med Chem Lett</source>
<year>2018</year>;<volume>9</volume>:<fpage>1045</fpage>.<pub-id pub-id-type="pmid">30344915</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melis</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Distinto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bianco</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Targeting tumor associated carbonic anhydrases IX and XII: highly isozyme selective coumarin and psoralen inhibitors</article-title>. <source>ACS Med Chem Lett</source>
<year>2018</year>;<volume>9</volume>:<fpage>725</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30034608</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Schr&#x000f6;dinger</surname><given-names>LLC</given-names></name></person-group>, New York, NY. <year>2018</year>.</mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohamadi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Richards</surname><given-names>NG</given-names></name>, <name name-style="western"><surname>Guida</surname><given-names>WC</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>MacroModel&#x02014;an integrated software system for modeling organic and bioorganic molecules using molecular mechanics</article-title>. <source>J Comput Chem</source>
<year>1990</year>;<volume>11</volume>:<fpage>440</fpage>&#x02013;<lpage>67</lpage>.</mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Guallar</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Berne</surname><given-names>BJ</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Importance of accurate charges in molecular docking: quantum mechanical/molecular mechanical (QM/MM) approach</article-title>. <source>J Comput Chem</source>
<year>2005</year>;<volume>26</volume>:<fpage>915</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">15841474</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Hah</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>AE</given-names></name></person-group>
<article-title>Correlation between performance of QM/MM docking and simple classification of binding sites</article-title>. <source>J Chem Inform Model</source>
<year>2009</year>;<volume>49</volume>:<fpage>2382</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jorgensen</surname><given-names>WL</given-names></name></person-group>
<chapter-title>OPLS force fields</chapter-title> In <person-group person-group-type="editor"><name name-style="western"><surname>Schleyer</surname><given-names>PvR</given-names></name></person-group>, ed. <source>Encyclopedia of Computational Chemistry</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Wiley</publisher-name>; <year>1998</year>:<fpage>1986</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akbaba</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ak&#x00131;nc&#x00131;o&#x0011f;lu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>G&#x000f6;&#x000e7;er</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitory properties of novel sulphonamide derivatives of aminoindanes and aminotetralins</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2014</year>;<volume>29</volume>:<fpage>35</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">23311862</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verpoorte</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Mehta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Edsall</surname><given-names>JT</given-names></name></person-group>
<article-title>Esterase activities of human carbonic anhydrases B and C</article-title>. <source>J Biol Chem</source>
<year>1967</year>;<volume>242</volume>:<fpage>4221</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">4964830</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bradford</surname><given-names>MM</given-names></name></person-group>
<article-title>A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding</article-title>. <source>Anal Biochem</source>
<year>1976</year>;<volume>72</volume>:<fpage>248</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">942051</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senturk</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gulcin</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Beydemir</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title><italic>In vitro</italic> inhibition of human carbonic anhydrase I and II isozymes with natural phenolic compounds</article-title>. <source>Chem Biol Drug Des</source>
<year>2011</year>;<volume>77</volume>:<fpage>494</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21332948</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meleddu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Petrikaite</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Distinto</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Investigating the anticancer activity of isatin/dihydropyrazole hybrids</article-title>. <source>ACS Med Chem Lett</source>
<year>2018</year>;<volume>10</volume>:<fpage>571</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">30996798</pub-id></mixed-citation></ref></ref-list></back></article>